The analysis suggested that bevacizumab inhibited VEGF activity during treatment by binding specifically to VEGF, blocking the nutrient supply to the tumor cell microenvironment, and thus controlling or delaying the formation and proliferation of abnormal neovascularization. The gene discussed is VEGFA; the disease is neoplasm.